

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novosom AG	07/27/2010
RECEIVING PARTY DATA	
Name:	Marina Biotech, Inc.
Street Address:	3830 Monte Villa Parkway
City:	Bothell
State/Country:	WASHINGTON
Postal Code:	98021
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12004154
CORRESPONDENCE DATA	
Fax Number:	(212)983-3115
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(212) 935-3000
Email:	sabelardo@mintz.com
Correspondent Name:	Mintz Levin Cohn Ferris et al.
Address Line 1:	666 Third Avenue-24th Floor
Address Line 4:	New York, NEW YORK 10017
ATTORNEY DOCKET NUMBER:	29627-207002US
NAME OF SUBMITTER:	Michelle A. Iwamoto
Total Attachments: 16 source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page1.tif source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page2.tif source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page3.tif source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page4.tif source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page5.tif	

CH \$40.00 12004154

501371497

PATENT
REEL: 025464 FRAME: 0450

source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page6.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page7.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page8.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page9.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page10.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page11.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page12.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page13.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page14.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page15.tif
source=29627-207002US_Recordation_Form_Cover_Sheet_and_Assignment#page16.tif

VIA ELECTRONIC FILING

Date of Filing: December 7, 2010

Attorney Docket No.: 29627-207002US

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

FORM PTO-1595
(Rev. 6-93)
OMB No. 0651-0011 (exp. 4/94)

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): NOVOSOM AG Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No 3. Nature of conveyance: ☒ Assignment ☐ Merger ☐ Security Agreement ☐ Change of Name ☐ Other Execution Date: See Above	2. Name and address of receiving party(ies) Name: MARINA BIOTECH, INC. 3830 Monte Villa Parkway Bothell, Washington 98021 Additional name(s) & address(es) attached? ☐ Yes ☒ No
---	---

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is _____

A. Patent Application No(s): **12/004,154, filed December 19, 2007**

B. Patent No(s):

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence Concerning document should be mailed: Name: Ivor R. Elrifi, Esq. Address: MINTZ, LEVIN, COHN, FERRIS GLOVSKY and POPEO, P.C. 666 Third Avenue - 24th Floor New York, New York 10017 Customer No. 35437	6. Total number of applications and patents involved: [<u>1</u>] 7. Total fee (37 CFR 3.41) \$40.00 ☒ Deposit Account No. 50-0311. ☒ The Commissioner is authorized to charge Deposit Account No: 50-0311, Reference No. 29627-207002US for any deficiencies.
---	---

DO NOT USE THIS SPACE

9. Statement and signature
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Michelle A. Iwamoto, Reg. No. 55,296	<i>Michelle A Iwamoto</i>	December 7, 2010
Name of Person Signing	Signature	Date

Total number of pages including cover sheet, attachments, and document: (16)

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES
Director of the United States Patent and Trademark Office
P. O. Box 1450
Alexandria, VA 22313-1450

EXHIBIT B

ASSIGNMENT AND ASSUMPTION AGREEMENT

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this "Assignment and Assumption Agreement") is made this 27th day of July, 2010 by and between NOVOSOM AG, a corporation organized under the laws of Germany (hereinafter referred to as "ASSIGNOR"), and MARINA BIOTECH, INC., a Delaware corporation (hereinafter referred to as "ASSIGNEE").

WITNESSETH

A. ASSIGNOR and ASSIGNEE are parties to that certain Asset Purchase Agreement dated as of even date herewith (the "Purchase Agreement") providing, among other things, for the sale by ASSIGNOR to ASSIGNEE of the Acquired Assets, and the transfer by ASSIGNOR to ASSIGNEE of the Assumed Liabilities.

B. Capitalized terms used but not otherwise defined in this Agreement shall have the same meaning ascribed to them in the Asset Purchase Agreement.

WITNESSETH, THAT FOR AND IN CONSIDERATION of the mutual promises contained in the Purchase Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by Assignors, and pursuant to the Purchase Agreement, Assignor hereby bargains, sells, assigns and transfers unto Assignee, its successors and assigns, all of Assignor's right, title and interest in and to and under the Acquired Contracts, including without limitation those Contracts set forth on Schedule 1.02 to the Purchase Agreement, but excluding the Excluded Contracts.

TO HAVE AND TO HOLD the same unto Assignee, its successors and assigns from and after the date hereof for all the rest of the respective terms of such Acquired Contracts (and any renewals, extensions and other options therein contained), subject to the covenants, conditions and provisions therein contained.

In addition, from time to time after the date hereof, without further consideration, Assignor shall execute and deliver such other instruments of assignment, transfer and conveyance and shall take such other action as Assignee may reasonably request to more effectively assign, transfer and convey to Assignee, all of Assignor's right, title and interest in and to any of the Acquired Contracts being assigned, transferred and conveyed to it hereunder, or to enable Assignee to exercise and enjoy all rights and benefits of Assignor with respect thereto.

ASSIGNEE hereby assumes and agrees to perform any and all liabilities and obligations under the Acquired Contracts included within the Assumed Liabilities.

Notwithstanding anything herein to the contrary, to the extent that any Acquired Contract

is not capable of being transferred by Assignor to Assignee pursuant to this Assignment and Assumption Agreement without the consent of a third party (including a governmental agency) and such consent has not been obtained prior to the date hereof, or if such transfer or attempted transfer would constitute a breach or violation of such Acquired Contract or of any law, nothing in this Assignment and Assumption Agreement will constitute a transfer or attempted transfer thereof. In the event that any such consent is not obtained, the provisions of Section 2.01(b) of the Purchase Agreement shall govern.

This Agreement shall inure to the benefit of and be binding upon Assignor and Assignee and their respective successors and assigns.


The rights and obligations of Assignor and Assignee set forth in the Purchase Agreement shall not be limited, altered, impaired, enhanced nor enlarged by this instrument. This instrument is subject to the terms and conditions of the Purchase Agreement and shall be governed and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles.

[remainder of page intentionally left blank; signature page follows]

IN WITNESS WHEREOF, and intending to be legally bound hereby, each of ASSIGNOR and ASSIGNEE has caused this Assignment and Assumption Agreement to be executed and delivered by its duly authorized representative as of the day and year first above written.

ASSIGNOR

NOVOSOM AG


By: 

Name: PAPTHERODOROU ELIAS

Title: CEO

ASSIGNEE

MARINA BIOTECH, INC.

By: 

Name: J. MICHAEL FRENCH

Title: PRESIDENT & CEO


EXHIBIT C

Form of Recordable Patent Assignment

For good and valuable consideration, the receipt of which is hereby acknowledged, NOVOSOM AG, a company established under the laws of Germany (hereinafter "Assignor"), hereby grants and assigns to MARINA BIOTECH, INC., a company established under the laws of the State of Delaware, United States of America (hereinafter "Assignee"), all of Assignor's right, title and interest (including rights of use) in and to the Patents Acquired identified in Attachment A hereto, to have and to hold the same, unto Assignee for its own use and enjoyment and for the use and enjoyment of its successors and assigns, for the full term or terms of all such rights.

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment to be duly signed on its behalf.

NOVOSOM AG


By: 


Name: PAPATHEODOROU, ILIAS
Title: CEO

Date: 07/27/2010

State of Massachusetts)
S.S.
County of Middlesex)

Before me this 27th day of July, 2010, personally appeared Ilias Papatheodorou, to me known to be the person(s) who are described in and who signed the foregoing Assignment and acknowledged to me that they signed the same of their own free will for the purpose therein expressed.


Notary Public



CONFIDENTIAL

Schedule 1.06 -- Acquired Intellectual Property

Acquired Patents

Reg ion	Patent Number	Serial / Appl Number	Title	Filing Date	Date of Patent
DE	DE 101 09 898.7		Lipide mit veränderlicher Ladung	21.02.2001	abandoned
WO	WO 02/066490	PCT/EP 02/01879	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	
EP	1 363 933	02 712 923.8-1211	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	6. Mai 09
AT	1 363 933	02 712 923.8 (EP 1 363 933)	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	see EP
CH	1 363 933	02 712 923.8 (EP 1 363 933)	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	see EP
DE	1 363 933	502 13 524.7-08 (EP 1 363 933)	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	see EP
FR	1 363 933	02 712 923.8 (EP 1 363 933)	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	see EP
GB	1 363 933	02 712 923.8 (EP 1 363 933)	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	see EP
NL	1 363 933	02 712 923.8 (EP 1 363 933)	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen	February 21, 2002	see EP

CONFIDENTIAL

JP	4470197	2002-566203 /204525902T2	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen / Cationic sterol derivatives, pH-sensitive liposomes comprising cationic sterol derivatives and method for loading	February 21, 2002	12. Mrz 10
US	7,312,206	10/468,652	Kationische Sterolderivate, pH-sensitive Liposomen umfassend diese und Verfahren zur Wirkstoffbeladung von Liposomen / Cationic sterol derivatives, pH-sensitive liposomes comprising cationic sterol derivatives and method for loading	February 21, 2002	25. Dez 07
US	20080113017A1	11/934,147	Sterol derivatives, liposomes comprising sterol derivatives and method for loading liposomes with active substances	February 21, 2002	abandoned
WO	WO 02/056489	PCT/EP 02/01878	Amphotere Sterole und deren Verwendung zur Herstellung von pH-sensitiven Liposomen	February 21, 2002	
AT	E430 759	E364620 / EP 1 363 932	Amphotere Sterole und deren Verwendung	February 21, 2002	see EP
AU	AU2002302364	2002302364	Amphotere Sterole und deren Verwendung zur Herstellung von pH-sensitiven Liposomen / Amphoteric sterols and the use thereof	February 21, 2002	17. Apr 08
BR		P10207776	Amphoteric sterols and the use thereof	February 21, 2002	abandoned
CA		2,438,910	Amphotere Sterole und deren Verwendung zur Herstellung von pH-sensitiven Liposomen / Amphoteric sterols and the use thereof	February 21, 2002	13. Okt 09
CH	1 363 932	02 729 931.2 / EP 1 363 932	Amphotere Sterole und deren Verwendung	February 21, 2002	see EP
CN	1231493C	02 805 320.6	Amphotere Sterole und deren Verwendung zur Herstellung von pH-sensitiven Liposomen / Amphoteric sterols and the use thereof	February 21, 2002	14. Dez 05
DE	1 363 932	502 10 313.2-08 / EP	Amphotere Sterole und deren Verwendung	February 21, 2002	see EP

3

PATENT
REEL: 025464 FRAME: 0459

CONFIDENTIAL

BE	1 363 601	02 701 290.5 / EP 1 363 601	use thereof Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
BR		PH0207775-2	Amphotere Liposomen und Verwendung dieser / Amphoteric liposomes and the use thereof	February 21, 2002	pending
CA		2,438,116	Amphotere Liposomen und Verwendung dieser / Amphoteric liposomes and the use thereof	February 21, 2002	pending
CH	1 363 601	02 701 290.5 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
CN	1241549C	02 805 213.7	Amphotere Liposomen und Verwendung dieser / Amphoteric liposomes and the use thereof	February 21, 2002	15. Feb 06
DE	1 363 601	502 10 271.3-08 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
EP	1 363 601	02 701 290.5 / EP 1363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	6. Jun 07
ES	1 363 601	02 701 290.5 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
FR	1 363 601	02 701 290.5 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
GB	1 363 601	02 701 290.5 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
IE	1 363 601	02 701 290.5 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP

CONFIDENTIAL

IT	1 363 601	02 701 290.5 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
JP	2004 525898	2002-565572	Amphotere Liposomen und Verwendung dieser / Amphoteric liposomes and the use thereof	February 21, 2002	pending
NL	1 363 601	02 701 290.5 / EP 1 363 601	Amphotere Liposomen und Verwendung dieser	February 21, 2002	see EP
SG	98827	200304631-5 (Patent 98827)	Amphotere Liposomen und Verwendung dieser / Amphoteric liposomes and the use thereof	February 21, 2002	31. Okt 07
US	2007/0269504	US 11/590,143	Divisional:Amphoteric liposomes and their use	31.10.2006	
US	2007/0252295	US 11/590,357	Continuation: Amphoteric liposomes	31.10.2006	allowable
US	2008/ 0031937	US 11/745,003	CIP: Amphoteric liposomes and their use	07.05.2007	pending
DE	DE 102 07 177.2		Fakultativ kationische Lipide	19.02.2002	abandoned
WO	WO 03/070220	PCT/EP03/01661	PH sensitiv kationische Lipide, Liposomen und Nanokapseln, die diese umfassen	February 19, 2003	
EP		03 742 540.2-2114	PH sensitiv kationische Lipide, Liposomen und Nanokapseln, die diese umfassen	February 19, 2003	abandoned
US	20060002991	10/505,107	PH sensitiv kationische Lipide, Liposomen und Nanokapseln, die diese umfassen / pH-sensitive Cationic Lipids, Liposomes and Nanocapsules containing the same	February 19, 2003	pending
AU	3219393AA		PH sensitiv kationische Lipide, Liposomen und Nanokapseln, die diese umfassen / pH-sensitive Cationic Lipids, Liposomes and Nanocapsules containing the same	February 19, 2003	abandoned
JP	2005 526727	2003-569178	PH-sensitive cationic lipids, and liposomes and nanocapsules containing the same	February 19, 2003	abandoned
DE	DE 102 07 178.0		Komponenten für die Herstellung amphoterer Liposomen	19.02.2002	abandoned
WO	WO 03/070735	PCT/EP03/01662	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	

CONFIDENTIAL

AT	E360635 (EP1478652)	03 742 541.0 (EP 1 478 652)	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	see EP
CH	1 478 652	03 742 541.0 (EP 1 478 652)	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	see EP
DE	1 478 652	503 07 127 7-08(EP 1 478 652)	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	see EP
EP	1 478 652	03 742 541.0 (EP 1 478 652)	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	25. Apr 07
FR	1 478 652	03 742 541.0 (EP 1 478 652)	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	see EP
GB	1 478 652	03 742 541.0 (EP 1 478 652)	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	see EP
JP	2005 517739	2003 - 569642	Components for producing amphoteric liposomes / Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	abandoned
NL	1 478 652	03 742 541.0 (EP 1 478 652)	Komponenten für die Herstellung amphoterer Liposomen	February 19, 2003	see EP
US	US 2005-0164963	10/505,093	Komponenten für die Herstellung amphoterer Liposomen / Components for producing amphoteric liposomes	February 19, 2003	pending
DE		10 2004 016 020.1-41	Serumstabile amphotere Liposomen / Serum-stable amphoteric liposomes	March 28, 2004	abandoned
DE		10 2004 054 730.0-41	Serumstabile amphotere Liposomen / Serum-stable amphoteric liposomes	November 05, 2004	abandoned
WO	WO 2005/094783 A2	PCT/DE2005/000589	Serumstabile amphotere Liposomen / Serum-stable amphoteric liposomes	March 29, 2005	

CONFIDENTIAL

EP1734928A2	05 740 433.7-2108	Serumstable amphotere Liposomen / Serum-stable amphoteric liposomes	March 29, 2005	pending
US20080311181A1	10/594,553 (PCT/DE2005/000589)	Serumstable amphotere Liposomen / Serum-stable amphoteric liposomes	March 29, 2005	pending
JP 2007530462T2	2007-504251	Serumstable amphotere Liposomen / Serum-stable amphoteric liposomes	March 29, 2005	abandoned
CA	2,561,247	Serumstable amphotere Liposomen / Serum-stable amphoteric liposomes	March 29, 2005	abandoned
AU	AU 5229485	Serumstable amphotere Liposomen / Serum-stable amphoteric liposomes	March 29, 2005	abandoned
IN	PCT/DE2005/000589	Serumstable amphotere Liposomen / Serum-stable amphoteric liposomes	March 29, 2005	abandoned
EP	EP 05 020 216.7	Serum stable liposomes comprising amphoter II lipid mixtures	15.09.2005	abandoned
US	US 60/717,291 prov.	Serum stable liposomes comprising amphoter II lipid mixtures	15.09.2005	abandoned
76a	EP 06 113 784.0 prov.	Serum stable liposomes comprising amphoter II lipid mixtures	10.05.2006	abandoned
WO	WO 07/031333	Improvements in or relating to amphoteric liposomes	15.09.2006	pending
US	US 2007-0104775	Improvements in or relating to amphoteric liposomes	15.09.2006	pending
EP	EP1764091		15.09.2006	pending
JP	JP 2009507876T2		15.09.2006	pending
AU	AU6291429		15.09.2006	pending
CA	CA 2,622,584		15.09.2006	pending
IN	IN 3046/DELNP/2008		15.09.2006	abandoned

*

CONFIDENTIAL

3046/DELNP/2008						
KR	KR 10-2008-7008987	KR 10-2008-7008987			15.09.2006	abandoned
US		US 60/625195	Systemic Delivery of CD40 Antisense		05.11.2004	abandoned
DE	DE 10 2006 013 121.5		Effizientes Verfahren zur Beladung von amphoteren Liposomen mit Nukleinsäure-Wirkstoffen		17.03.2006	abandoned
DE	DE 10 2006 054 192.8		Effizientes Verfahren zur Beladung von amphoteren Liposomen mit Nukleinsäure-Wirkstoffen		10.11.2006	abandoned
WO	WO 07/107304	WO2007EP0002349	An efficient method for loading amphoteric liposomes with nucleic acid active substances		16.03.2007	
* EP	EP 07723327.8	EP2004141			16.03.2007	pending
	US	12/225030			16.03.2007	pending
	unfiled		Improvements in or relating to methods for producing liposomes			abandoned
EP	EP 06 255 277.3	EP1 911 443	Amphoteric liposomes, method of formulating an amphoteric liposomes and a method of loading an amphoteric liposome		13.10.2006	abandoned
US	US 2008/0088046	11/581,054	Improvements in or relating to amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome		13.10.2006	pending
* WO	WO 08/043575	PCT/EP2007/008917	Improvements in or relating to amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome		12.10.2007	
* EP	EP2094238	EP 07818988.3			12.10.2007	pending
CA	CA	CA2665783			12.10.2007	pending

CONFIDENTIAL

JP	JP				12.10.2007	pending
AU	AU	AU2007306556			12.10.2007	pending
KR	KR					abandoned
US	US	US2008/0089932	11/974,350	CIP related to US11/581,054	12.10.2007	pending
EP	EP	EP 08 007 302.6		improvements in or relating to amphoterics liposomes comprising neutral lipids	11.04.2008	abandoned
WO	WO	WO2008EP0008621		improvements in or relating to amphoterics liposomes comprising neutral lipids	12.10.2008	
		2009047006A2				
AU	AU	AU 2008309880		Amphoterics liposomes comprising neutral lipids	07.04.2010	pending
US	US	US xxx	12/682,703	CIP to Algorithm case, identical spec with WO2009047006	12.04.2010	pending
EP	EP	EP 06 256 450.5		Lipids and lipids assemblies comprising transfection enhancer elements	19.12.2006	abandoned
US	US	US 11/624,347		Lipids and lipids assemblies comprising transfection enhancer elements	19.12.2006	abandoned
EP	EP	EP 07117189.6		Lipids and lipids assemblies comprising transfection enhancer elements	25.09.2007	abandoned
WO	WO	WO 08/074487	PCT/EP2007/011187	Lipids and lipids assemblies comprising transfection enhancer elements	19.12.2007	
EP	EP	EP 2125091	07856910.0		19.12.2007	pending
JP	JP		2009-541876		19.12.2007	pending
US	US	US 12/004,154		CIP zur ersten US: Lipids and lipids assemblies comprising transfection enhancer elements	19.12.2007	pending
DE	DE			Emulation of lipoproteins	09.07.2009	abandoned
EP	EP	EP 09 165 106.7		Emulation of Lipoprotein Structures	9. Juli 2009	pending

*

CONFIDENTIAL

pending

23.09.2009

02.07.2010

02.07.2010

abandoned

19.12.2006

19.12.2007

19.12.2007

19.12.2007

19.12.2007

19.12.2007

19.12.2007

abandoned

11.07.2008

July 13, 2009

Date of Patent

Filing Date

01.12.2005

01.12.2006

Amphoteric liposomes comprising imino lipids

Emulation of lipoprotein structures

Construction and Use of Transfection Enhancer elements

Construction and Use of Transfection Enhancer elements

Cell penetrating nucleic acids

Cell Penetrating Nucleic Acid

Title

Serial

Nr.

US 60/741,192

US prov.

WO 07/064857

Amphoteric Liposome Formulation

Amphoteric Liposome Formulation (Pronal)

EP 06 844 698.8

US 12/085,893

JP 2008 543480

CA 263 1677

Acquired Trademarks

Region Docket

Registered number

Date of Filing

Trademark

DE M167307DE-Ma

399 80 102.2/05

December 16, 1999

SMARTICLES (Wort)

PATENT

REEL: 025464 FRAME: 0466

CONFIDENTIAL

EP	M167307EU-Ma	006 003 032	June 14, 2007	SMARTICLES (Wort)
US	M167307US-Ma	77/210800	June 20, 2007	SMARTICLES (Wort)

Acquired Trade Secrets

"Amphoteric liposomes comprising fatty acids" according to inventor's note dated May 19th, 2009

Acquired Copyrights

No items listed